Newsletter sign up


ADC University Our services

ADC Review
is made possible by:



Copyright 2017
Terms & Conditions


Brentuximab Vedotin (Adcetris®) Clinical Trials

Trial Title Study Record Detail Phase Sponsor/Collaborator
SGN35-013 Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies NCT01461538 Phase II Seattle Genetics
Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma NCT01393717 Phase II City of Hope Medical Center, National Cancer Institute (NCI)
SGN35-012 A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma NCT01421667 Phase II Seattle Genetics, Inc
Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas NCT01805037 Phase I, Phase II Northwestern University and Seattle Genetics, Inc.
Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL) NCT01657331 Phase I, Phase II Owen A. O’Connor, British Columbia Cancer Agency, Princess Margaret Hospital, Canada and Columbia University
Phase I Trial of Brentuximab Vedotin for Refractory Chronic Graft-vs.-Host Disease (GVHD) NCT01940796 Phase I Massachusetts General Hospital, Seattle Genetics, Inc
Brentuximab Vedotin in Treating Patients With Steroid-Resistant Acute Graft-Versus-Host Disease NCT01616680 Withdrawn Phase II Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, National Cancer Institute (NCI), Fred Hutchinson Cancer Research Center
Phase I/II – Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML) NCT02096042 Phase I, Phase II M.D. Anderson Cancer Center, Seattle Genetics, Inc.
Study of Brentuximab Vedotin (SGN-35) in Pediatric Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma NCT01492088 Phase I, Phase II Millennium Pharmaceuticals, Inc
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma NCT01771107 Phase I, Phase II National Cancer Institute (NCI)
Brentuximab Vedotin Prevention of (GVHD) After Unrelated Allogeneic Stem Cell Transplantation NCT01700751 Phase 0 Washington University School of Medicine
Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin Lymphoma NCT01900496 Phase 0 Sidney Kimmel Comprehensive Cancer Center
A Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma NCT01990534 Phase IV Millennium Pharmaceuticals, Inc.
Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35) NCT01026415 Phase I Seattle Genetics, Inc, Millennium Pharmaceuticals, Inc.
A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage III-IV HIV-associated Hodgkin Lymphoma NCT02298257 Phase II The Lymphoma Academic Research Organisation
Brentuximab Vedotin (SGN-35) as Salvage Treatment for CD30-positive Germ Cell Tumors NCT01851200 Phase II Fondazione Michelangelo, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Millennium Pharmaceuticals, Inc.
Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma NCT02254239 Phase I Mayo Clinic, National Cancer Institute (NCI)
Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma NCT01780662 Phase I, Phase II National Cancer Institute (NCI)
Ipilimumab and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma NCT01896999 Suspended Phase I National Cancer Institute (NCI)
Brentuximab Vedotin After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies NCT01620229 Withdrawn Phase I, Phase II Fred Hutchinson Cancer Research Center, Seattle Genetics, Inc, National Cancer Institute (NCI)
Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT) NCT02169505 Phase II M.D. Anderson Cancer Center
Brentuximab Vedotin in CD30 Positive Epstein Barr Virus (EBV) Positive DLBCL of Elderly NCT01671813 Withdrawn H. Lee Moffitt Cancer Center and Research Institute, Seattle Genetics, Inc
Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin’s Lymphoma Patients NCT02164006 Phase I TG Therapeutics, Inc.
ALCANZA A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician’s Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma NCT01578499 Phase III Millennium Pharmaceuticals, Inc, Seattle Genetics, Inc.
Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma NCT02086604 Phase I Washington University School of Medicine
Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma NCT02227199 Phase I, Phase II University of Washington, National Cancer Institute (NCI)
Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma NCT01508312 Phase I Memorial Sloan Kettering Cancer Center, Seattle Genetics, Inc.
Brentuximab Vedotin (Recombinant) for IV Infusion – Special Drug Use Surveillance (All-case Surveillance) “Relapsed or Refractory CD30+ Hodgkin’s Lymphoma or Anaplastic Large Cell Lymphoma” NCT02139592 Takeda
SGN35-015 A Study of Brentuximab Vedotin in Adults Age 60 and Above With Newly Diagnosed Hodgkin Lymphoma (HL) NCT01716806 Phase III Seattle Genetics, Inc.
Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia NCT01807598 Jason Robert Gotlib, National Cancer Institute (NCI), Stanford University
Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma NCT01920932 Phase II St. Jude Children’s Research Hospital|Seattle Genetics, Inc.
SGN35-016 Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma NCT01874054 Phase I |Phase II Seattle Genetics, Inc.
Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma NCT01979536 Phase I National Cancer Institute (NCI)
Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma NCT01902160 Phase I National Cancer Institute (NCI)
To Assess the Efficacy of Brentuximab Vedotin for Relapsed/Refractory CD30-positive Non-Hodgkin Lymphomas Other Than Anaplastic Large Cell Lymphoma NCT02280785 Phase II Samsung Medical Center, Millennium Pharmaceuticals, Inc.
Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma NCT01909934 Phase IV Millennium Pharmaceuticals, Inc.
SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma NCT00365274 Phase II National Cancer Institute (NCI)
SGN35-017 Study of Brentuximab Vedotin Combined With RCHOP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL) NCT01925612 Phase II Seattle Genetics, Inc.
A Phase II Study of Brentuximab Vedotin (BV) in the Treatment of Elderly Hodgkin Lymphoma (HL) Patients at First Relapse or With Primary Refractory Disease. NCT02227433 Phase II Fondazione Italiana Linfomi ONLUS
Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients NCT02280993 Phase II Marjolein Spiering, Millennium: The Takeda Oncology Company, Academisch Medisch Centrum (Universiteit van Amsterdam/AMC-UvA)
A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma NCT01060904 Phase I Seattle Genetics, Inc, Millennium Pharmaceuticals, Inc.
Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30 NCT01841021 H. Lee Moffitt Cancer Center and Research Institute, Seattle Genetics, Inc.
A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma NCT01950364 Phase I Millennium Pharmaceuticals, Inc
A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms NCT01309789 Phase I Seattle Genetics, Inc, Millennium Pharmaceuticals, Inc.
Evaluation Study of Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory HL NCT02243436 Phase I |Phase II Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea, Millennium Pharmaceuticals, Inc.
Brentuximab Vedotin + Chemo for AML NCT01830777 Phase I Massachusetts General Hospital
Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma NCT00354107 Terminated National Cancer Institute (NCI)
Brentuximab Vedotin and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Hodgkin Lymphoma NCT02166463 Phase III National Cancer Institute (NCI)
Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma NCT01578967 UNC Lineberger Comprehensive Cancer Center, Seattle Genetics, Inc.
Brentuximab Vedotin Followed by ABVD in Patients With Previously Untreated Hodgkin Lymphoma NCT02275598 Phase II : University of Modena and Reggio Emilia, Millennium Pharmaceuticals, Inc.
Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD NCT02298283 Phase II The Lymphoma Academic Research Organisation
Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma NCT02191930 Phase II University of Cologne (Germany)
Brentuximab Vedotin in Treating Patients With Relapsed or Refractory CD30+ Lymphoma NCT01703949 University of Washington, National Cancer Institute (NCI)
SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma NCT00337194 Phase II National Cancer Institute (NCI)
ECHELON-2 ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas NCT01777152 Phase III Seattle Genetics, Inc, Millennium Pharmaceuticals, Inc.
Brentuximab Vedotin for Steroid Refractory GvHD NCT01596218 Phase I Massachusetts General Hospital, Seattle Genetics, Inc, Dana-Farber Cancer Institute
A Pilot Phase II Study With BRENTUXIMAB VEDOTIN as Pre-ASCT Induction Therapy in Relapsed/Refractory Hodgkin’s Lymphoma Patients Non Responding to IGEV Salvage Treatment NCT02244021 Phase II Fondazione Italiana Linfomi ONLUS
Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma NCT01534078 Phase II Massachusetts General Hospital, Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, H. Lee Moffitt Cancer Center and Research Institute, Seattle Genetics, Inc

SG035-0004

A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma NCT00866047 Phase II Seattle Genetics, Inc., Millennium Pharmaceuticals, Inc.
Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma NCT00099255 Phase II Seattle Genetics, Inc.
Cardiac Safety Study of Brentuximab Vedotin (SGN-35) NCT01026233 Phase I Seattle Genetics, Inc, Millennium Pharmaceuticals, Inc.
Brentuximab Vedotin Combined With AVD Chemotherapy and 30 Gray Involved-Site Radiotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma NCT01868451 Memorial Sloan Kettering Cancer Center, Seattle Genetics, Inc, University of Rochester
Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma. NCT02292979 Phase II The Lymphoma Academic Research Organisation, Millennium Pharmaceuticals, Inc.
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study NCT00947856 Phase II Seattle Genetics, Inc., Millennium Pharmaceuticals, Inc.

SG035-0003

A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma NCT00848926 Phase II Seattle Genetics, Inc.|Millennium Pharmaceuticals, Inc.
Pilot Study of Brentuximab Vedotin (SGN-35) in Patients With MF With Variable CD30 Expression Level NCT01396070 Youn Kim, Seattle Genetics, Inc., Stanford University
A Phase I/II Study Of Brentuximab Vedotin In Combination With Multi-Agent Chemotherapy As Front-Line Treatment In Patients With CD30 Positive Primary Mediastinal Large B-Cell, Diffuse Large B-Cell, And Grey Zone Lymphomas NCT01994850 Phase I, Phase II Abramson Cancer Center of the University of Pennsylvania
Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients NCT02098512 Phase I, Phase II New York Medical College, St. Baldrick’s Foundation
Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma NCT01476410 Phase II Northwestern University, Robert H. Lurie Cancer Center, Seattle Genetics, Inc.
ECHELON-1 Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma NCT01712490 Phase III Millennium Pharmaceuticals, Inc, Seattle Genetics, Inc.
SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP) NCT01352520 Phase II M.D. Anderson Cancer Center, Seattle Genetics, Inc.
AETHERASGN35-005 A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial) NCT01100502 Phase III Seattle Genetics, Inc, Millennium Pharmaceuticals, Inc.
A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies NCT00051597 Phase I, Phase II Seattle Genetics, Inc
Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell Lymphoma NCT00079755 Phase II Seattle Genetics, Inc.
A Treatment-Option Study of Brentuximab Vedotin in Patients With Progression of Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma NCT01196208 Seattle Genetics, Inc, Millennium Pharmaceuticals, Inc.
Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma NCT01569204 Phase II University of Cologne
A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies NCT00649584 Phase I Seattle Genetics, Inc
Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies NCT00430846 Phase I Seattle Genetics, Inc.

Last Editorial Review: August 11, 2015


Manuscript Guidelines & Tips Lonza

Featured Event

Topics to be Covered Introduction To Antibody Conjugates Overview Of Techniques In Quantitative Pharmacology No Such Thing As A Magic Bullet: The Hidden Challenges Of ADC Discovery And Development...


Skip to toolbar